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In recent years, pharmacovigilance has undergone some major changes. First, the
patient’s active role in identifying and describing adverse drug reactions (ADRs)
has gained recognition. Second, pharmacovigilance has increasingly incorporated
information and communications technology (ICT). Patients can now upload their own
reports of ADRs online. Data on intensive medication monitoring are now collected via
the Internet and smartphones. Worldwide collection of AEs using smart phones might
become the leading technique in Low and Middle Income Countries where broad mobile
phone service can be managed cheaper than Internet communication. At the same time,
researchers are exploring the potential for data sharing via online forums and Internet
search engines. In particular we synthetize the Pros and cons of the various methods for
gathering pharmacovigilance data (i.e., Web-based spontaneous reporting of adverse
drug reactions; Intensive drug monitoring studies; Analysis of online forum postings; Use
of mobile phone systems to monitor drug effects). This article describes these advances
and highlights their respective contributions.
Keywords: pharmacovigilance, adverse drug reactions, adverse events, patient participation, web-based
reporting, ehealth, intensive medication monitoring, mobile apps
INTRODUCTION
Pharmacovigilance, or the practice of monitoring the effects of drugs, including the detection,
assessment, understanding, and prevention of adverse events (AEs), is undergoing major
changes. Until recently, pharmacovigilance drew mainly on spontaneous reports by health-care
professionals (H), but lately, patients themselves are reporting adverse drug reactions (ADRs),
and all these reports can be uploaded directly online via the Internet, tablets, and smartphones.
Meanwhile, other ehealth tools are being used to complement these reports. Gathering as much
information as possible on ADRs is vital for public health due to the significant consequences for
health: ADRs account for 3% of hospitalisations in France, and they are one of the 10 leading
causes of morbidity and mortality in the United States (USA) (Bousquet et al., 2011). The associated
economic burden is also considerable. For example, in the USA, the cost exceeded $177.4 billion in
2000 alone (Ernst and Grizzle, 2001). However, most countries have not kept records of the cost of
ADRs.
This article examines the contribution of patient participation and the use of ehealth tools for
pharmacovigilance. The following questions are addressed:
– In what ways can patients participate in drug monitoring?
– Does patient participation improve pharmacovigilance?
– What ehealth tools effectively enable patient participation?
– Do ehealth tools contribute significantly to ADR detection?
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A targeted literature search is presented, based on
an article search within the MEDLINE database using
the following keywords: pharmacovigilance AND ehealth
(2)/pharmacovigilance AND Internet (72)/pharmacovigilance
AND mobile phone (4)/pharmacovigilance AND smartphone
(4)/pharmacovigilance AND apps (0), pharmacovigilance AND
adverse drug reactions reported by consumers (18)/adverse drug
reaction reporting AND patients AND Internet (38)/adverse
drug reactions AND patient-reported (150)/drug monitoring
AND mobile phone (62)/adverse drug reaction AND mobile
phone (13).
The literature search covered articles published from January
2000 to January 2015. The MEDLINE search obtained 363
references. The abstracts of identified articles were then assessed
for relevance. Studies were included if they contained theoretical
or empirical data on patients’ reports of ADRs or investigations
of ADRs using ehealth methods (e.g., Internet, smart devices,
smartphones). Complete articles were obtained for each selected
study. The references for each article were further searched
to identify additional relevant articles. In all, 51 articles were
included in the review.
PATIENT PARTICIPATION IN
PHARMACOVIGILANCE
Pharmacovigilance can be achieved by different methods, for
example, cohort studies. However, the most commonly used
method is spontaneous reporting of ADRs (Bandekar et al.,
2010). This type of reporting has been described as an effective
way to detect safety signals for medications (Ribeiro-Vaz
et al., 2012). Most countries have a national pharmacovigilance
program for gathering spontaneous ADR reports, analysing
causal associations with drugs, and transmitting information to
authorities. Currently, the Uppsala (2014) Monitoring Centre
(the WHO centre for international drug monitoring, Uppsala,
Sweden) is receiving data from120 participating countries. Data
are pooled and ADRs are monitored using a data mining
approach. Information on ADRs is then transmitted back to the
national pharmacovigilance centers (Bandekar et al., 2010).
Until recently, European pharmacovigilance centers have
relied exclusively on HCPs to report ADRs. However, since July
2012, the European Commission has allowed patients to make
their own reports. It is notable that this decision lagged far
behind those of other countries, including Australia, Canada,
New Zealand, and the USA, which have been taking patients’
reports into account since the 1960s (van Hunsel et al., 2012).
The new European regulations reflect the fact that in
pharmacovigilance, as in other healthcare areas, growing
importance has been given to patient-reported information.
According to Banerjee and Ingate (2012), patient-reported
outcomes (PROs) via Internet channels have become increasingly
important, enabling regulators to understand the real-world
benefits and risks of medications. Nevertheless, despite the
greater attention that patient reports are receiving, their full
potential has yet to be realized in pharmacovigilance (Banerjee
et al., 2013). At this point, safety reports and risk assessment
procedures depend heavily on HCPs, despite the known
limitations. For instance, underreporting by HCPs is a well-
known problem (Hasford et al., 2002; Hazell and Shakir, 2006;
Lopez-Gonzalez et al., 2009; Gonzalez-Rubio et al., 2011; Hanafi
et al., 2012). Yet, given the clinical relevance of real-world
data, patient reports could make a significant contribution to
advance the knowledge on drug benefits and risks. Against
this background, the Patient-Reported Outcomes Safety Event
Reporting (PROSPER) Consortium was convened. Its aim is to
improve safety reporting by better incorporating the patient’s
perspective. PROSPER includes representatives from industry,
regulatory authorities, the private sector, and academia as well as
patients. It supports wider use of patient-reported outcomes of
adverse events (PRO-AEs), and it has recently (from July 2011 to
March 2013) developed guidelines, including the benefits of wider
use and approaches for data capture and analysis.
In sum, the vital role that patients can play in the
identification, description, and ultimately prevention of drug-
related harm is increasingly being valued.
USE OF EHEALTH TOOLS TO
FACILITATE PATIENT PARTICIPATION IN
PHARMACOVIGILANCE
Another recent development is the use of information and
communication technology (ICT) tools to gather data on
the AEs of marketed drugs. According to Cobert and Silvey
(1999), Internet-based methods to ensure drug safety and
pharmacovigilance are spreading rapidly. Pharmacovigilance
agency websites are ever more welcoming of spontaneous ADR
reports. Meanwhile, new mobile apps are being developed to
allow ADR reporting anywhere, anytime. Besides spontaneous
reports, studies have proposed more intensive ADR monitoring
by following specific patient groups over time, which would also
involve web-based data gathering. In addition, some researchers
(Schröder et al., 2007; White et al., 2013; Abou Taam et al., 2014)
have advocated online forum analysis as a supplementary ADR
data source.
The remainder of this article describes these new approaches.
Spontaneous Online Reports of ADRs
Inch et al. (2012) noted that national pharmacovigilance
programs are welcoming more patient reports of ADRs.
Moreover, these reports are more commonly submitted online
in countries such as the USA, Canada, Australia, New Zealand,
Kenya, and Malaysia. The US Food and Drug Administration
(FDA) has been gathering ADR reports from both HCPs and
consumers since its inception in the 1960s. Reports can be
submitted by phone or email or uploaded directly online.
The ability to report online has increased the number of
reports, especially by HCPs. For instance, Abadie et al. (2014)
noted that once online notifications were introduced, reports by
ambulatory HCPs increased by 45%.
In Europe, ways for HCPs to report ADRs online are
proliferating. For example, in Belgium, the Federal Agency for
Medicines and Health Products (FAMHP) has provided ADR
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report forms on its website since 2012. Since 2008, Swedish
consumers can report ADRs to the Medical Products Agency
(MPA), and since 2002, reports can be sent via an online form
to the independent non-profit organization called the Consumer
Association for Medicines and Health (KILEN). The United
Kingdom (UK) has set up a reporting site called the Yellow
Card Scheme (YCS) (Avery et al., 2011), where reports are
passed on to the Medicines and Healthcare products Regulatory
Agency (MHRA) by mail, phone, or Internet. To further
develop pharmacovigilance capabilities, Europe has initiated an
online platform called European Union Adverse Drug Reactions
(EU-DR). The aim is to facilitate data access, data management,
and data search to enable more in-depth examinations of
ADR risks (Oliveira et al., 2013). The Netherlands, Denmark,
Italy, and France have also developed online reporting systems
(Herxheimer et al., 2010). However, some websites do not provide
an online reporting form as such: visitors must download a form,
complete it, and e-mail it.
So far, each country has been using its own ADR reporting
system, and they do not all have the same data. Bandekar et al.
(2010) compared online reporting forms across 10 different
countries (India, Pakistan, USA, Great Britain, Kenya, Malaysia,
Canada, Australia, South Africa, and Tanzania) in terms of
18 points deemed essential for good ADR reporting (e.g.,
information on allergies, diagnosis, drug dose and frequency,
adequate space provided to capture reactions). Of the analyzed
forms, Malaysia earned the highest score (16 out of 18 points).
Unlike most of the other countries, its form addressed severity
and causality. At the other extreme, Pakistan earned only 6 out
of 18 points. This study reveals the need to harmonize ADR
reporting forms across countries.
The above-cited studies attest that Europe and many other
countries are gradually improving their online systems for patient
reporting of ADRs.
Once it has been decided to involve patients in the
pharmacovigilance process, a number of questions arise:
– Compared to reports by healthcare professionals (HCPs),
do patient reports make a significant contribution to
pharmacovigilance?
– What motivates patients to make spontaneous reports?
The Contribution of Spontaneous Patient Reports
Overall, studies that considered paper, online, and phone reports
have shown that patient reports provide useful information that
supplements HCP reports and helps identify new potential ADRs
(Blenkinsopp et al., 2007; van Geffen et al., 2007; van Hunsel et al.,
2009; Avery et al., 2011; Vilhelmsson et al., 2011).
Inch et al. (2012), in a systematic review of comparative
studies of patient and HCP reports (paper, online, and phone)
to national pharmacovigilance schemes, showed both similarities,
and differences across schemes. Patients and HCPs reported
similar percentages of serious ADRs in total numbers of
ADR reports, but this percentage differed across studies. The
Netherlands and the UK showed similarities in terms of reported
drugs. The UK and Denmark showed clear differences between
patients and HCPs in the body systems affected by ADRs, despite
the considerably similar nature of the ADRs. The Dutch study
also showed that patients and physicians reported ADRs for
similar types of drugs.
Avery et al. (2011) noted that previous studies showed
differences between patient and HCP reports in terms of reported
drug types and reactions. They compared reports (paper, online,
and phone) submitted by 5,180 patients and 20,949 HCPs from
October 2005 to September 2007 to the YCS. Compared to HCP
reports, patient reports contained a higher median number of
suspected ADRs per report, with more detailed descriptions.
Proportions of “serious” reports were similar for patients and
HCPs, but drug and reaction patterns differed. Patient reports
contained more detailed descriptions of reactions and more
mentions of the effects on patients’ lives. Combining patient and
HCP reports would generate new potential signals compared
to HCP reports alone. Supplemental reports by patients have
enabled identifying 47 new serious reactions not previously
included in “Summaries of Product Characteristics”.
Some studies have examined reports on specific medication
types. They also found differences between patient and HCP
reports, highlighting the contribution of patient-provided
information. For example, van Geffen et al. (2007) focused
on ADRs associated with antidepressants in a comparison of
patient- and HCP-reported ADRs via an Internet-based system
of reporting to the Netherlands Pharmacovigilance Centre Lareb
from May 2004 to May 2005. Compared to HCP reports,
patient reports more often mentioned apathy, excessive sweating,
ineffectiveness, somnolence, insomnia, sexual problems, and
weight gain. In conclusion, patient and HCP reports may differ in
the nature of ADRs. Vilhelmsson et al. (2011, 2012) also examined
reports on antidepressants. Vilhelmsson et al. (2011) analyzed all
reports submitted from January 2002 to April 2003 to an open
Swedish website where anyone could report their experience
with medications. Of a total of 665 reports, 442 concerned
antidepressants, representing 2,394 ADRs, of which 878 (37%)
were psychiatric effects. The conclusion was that consumer
reports may contribute important information on more serious
psychiatric ADRs following traditional antidepressant treatment.
In another study, Vilhelmsson et al. (2012) interpreted the
content of 181 online reports submitted to KILEN from
January 2002 to April 2009 and concerning suspected ADRs
for antidepressants. The results showed that free text comments
in patient report forms can be valuable for pharmacovigilance,
and can provide important information on how drugs may
affect individuals and their lives. The majority of patient
reports mentioned symptoms of mental disturbances (sometimes
severe), which affected them in various ways, especially when the
medications were discontinued. Patients often stated that they
received no information on potential ADRs from their doctor,
and what is more, received no follow-up. Some patients also
reported losing confidence in their doctors, who did not believe
their reports of experienced ADRs, which led patients to attempt
to discontinue treatment.
van Hunsel et al. (2009) analyzed ADR reports on statins,
a class of drugs used to help lower blood cholesterol levels.
They examined reports submitted to the Lareb Centre in the
Netherlands after a TV program called Radar was broadcast on
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the benefits and risks of statins. The authors compared online
patient reports with online and paper reports by HCPs. Results
suggested that the media attention temporarily increased patient
reports, whereas HCP reports remained as usual. In terms of
seriousness and number of drug cessations, patient and HCP
reports were similar. However, patients reported non-recovery
more often than HCPs.
In light of these studies, consumer and HCP reports appear to
differ both quantitatively and qualitatively. At the same time, the
supplementary information provided by patients was considered
useful for improving drug monitoring.
Given the attention that is being paid to patient reports, it
would be important to better inform consumers about reporting
systems. At this point, few patients know that they can submit
self-reports of ADRs. For example, in the UK, the majority of
patients are unaware of this possibility (Fortnum et al., 2012 cited
in van Hunsel et al., 2012). In 2009, only 8.5% of individuals
knew about the YCS (Avery et al., 2011). In Korea, Lee et al.
(2012) analyzed spontaneous online reports from January to
December 2008. Of the 933 cases of ADRs reported, 53% were
made by doctors, 31% by pharmacists, 13% by nurses, and only
3% by the public. In addition, the number of patient reports
varies widely across countries. For example, a considerably
higher percentage of patients submits reports (mail, phone, and
online) in Denmark. In 2008, of 2,925 reports received, 72%
were made by doctors, 2% by pharmacists, 6% by other HCPs
(nurses, dentists), and 19% by patients (Herxheimer et al., 2010).
van Hunsel et al. (2012) noted that most of the 11 countries
included in their review (Australia, Canada, Denmark, Malaysia,
the Netherlands, New Zealand, Norway, the Philippines, Sweden,
the UK, and the USA) ideally wanted to spend more on public
awareness campaigns to generate more patient ADR reports.
Patient Motivations to Make Spontaneous Reports
For purposes of increasing consumer participation, it would be
useful to gain a deeper understanding of what motivates patients
to make spontaneous reports. In this perspective, van Hunsel
et al. (2010) investigated the motives behind patient reports of
ADRs to a pharmacovigilance center in the Netherlands. An
online questionnaire was sent to 1,370 patients who had made
previous reports from January 2008 to March 2009, for a response
rate of 76.5%. The main motives for patient reporting were a
desire to share their experience, the severity of the ADR, worries
about their own situation, and the lack of warning information in
the patient leaflet. Of the respondents, 93.8% agreed that ADR
reports can prevent harm to other people, 97.9% believed that
their reports contributed to research and knowledge, 90.7% felt
responsible for reporting ADRs, and 92.5% intended to report
ADRs in future. These concerns are similar to those observed in
HCPs. Biriell and Edwards (1997) explored positive reasons for
physicians and pharmacists to take the time to report ADRs, both
online and not. The reasons were classified into 14 categories,
with most falling into the top six: motivation to contribute to
medical knowledge, reaction previously unknown to the reporter,
reaction to a new drug, all significant reactions reported, known
association between a drug and a reaction, and severity of the
reaction.
Aside from motivations, it would be instructive to understand
more about the factors that influence consumers to report ADRs.
These factors could be somewhat similar to those that influence
HCTs. For example, Lopez-Gonzalez et al. (2009) conducted a
systematic review of the underlying determinants for HCPs. They
found that medical speciality was the professional characteristic
that was most closely associated with under-reporting in 76%
of studies involving physicians. Other factors associated with
under-reporting were the fact that only the most severe ADRs
were reported, diffidence (fear of ridicule for reporting merely
suspected ADRs), lethargy (a combination of procrastination,
lack of interest or time to find a report card, etc.), indifference
(it is almost impossible to determine whether a medication is
responsible for a particular ADR), and complacency (only “safe”
drugs are assumed to be allowed on the market).
It appears that patients are driven by many motivations to
make spontaneous ADR reports. Some patient motivations are
similar to those expressed by physicians, such as severity of the
ADR, a desire to contribute to medical knowledge, and the fact
the certain ADRs are not yet well known or mentioned in the
explanatory leaflet. However, patients also appear to have purely
altruistic motives.
Apart from spontaneous ADR reports, more systematic and
targeted data gathering methods have been implemented to
monitor ADRs for specific marketed drugs. Generally known
as intensive medication monitoring, these methods complement
spontaneous reports. They involve observing a cohort over time
without intervention in order to monitor a particular drug.
The advantage is that it allows gathering follow-up data over
time, which is rarely the case for spontaneous reports. Intensive
monitoring systems have been set up in the Netherlands, the UK,
and New Zealand, for example.
Web-Based Intensive Monitoring
Härmark and van Grootheest (2012) presented an overview of
the results of web-based intensive monitoring as well as the
pros and cons. This method uses a specific inclusion point, such
as an eligibility criterion that patients are using a medication
for the first time, and eligible patients are identified when
they present their prescriptions at pharmacies. Patients are
followed over time using web-based questionnaires to gather
information about drug use and ADRs. The main expert opinion
is that this type of intensive monitoring, which lets patients
be the information source, can be useful for postmarketing
monitoring. For instance, it can address other aspects besides
ADRs, such as indications for use and off-label use, dosage, and
compliance.
According to Härmark et al. (2011a), web-based intensive
monitoring allows gathering longitudinal safety data on drugs
and examining the time course of ADRs. It can make a valuable
contribution to pharmacovigilance because it generates more
types of information compared to spontaneous reports and
other intensive monitoring methods. For example, in the case
of pregabalin, Härmark et al. (2011b) showed that a web-
based intensive monitoring system can advance the knowledge
on ADRs, such as headache, while providing quantified data
and information on the time to onset of the ADR and
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its evolution over time. Participants were first-time users of
pregabalin and were identified by their prescription filled at
participating pharmacies. After online registration, participants
received emailed questionnaires 2 weeks, 6 weeks, 3 months, and
6 months after beginning treatment. This type of system can
also be used to identify signals that merit further investigation,
for example, abdominal pain or potential interactions with oral
antidiabetics. In another study, Härmark et al. (2011c) used a
similar web-based intensive monitoring system in over 3,000
patients who were vaccinated against the pandemic influenza A
(H1N1) virus in general practice. They found that more than
a third of the patients (37%) reported adverse events following
immunisations (AEFIs). No unexpected serious reactions were
reported, nor were signals of possible new AEFIs. Broos et al.
(2010) also demonstrated the usefulness of an online survey
for rapid gathering of information about vaccine safety, in this
case, the H1N1 vaccine administered to children aged 6 months
to 4 years. From a survey emailed to the vaccinated children’s
parents who reported fever to Lareb after the first immunization,
the researchers found that 56.2% of these children had a fever
that peaked at from 39.0 to 40.0 40◦C, of which 70.4% recovered
within 2 days.
According to Härmark et al. (2013a), little is known about
patients’ motivations to participate in web-based postmarketing
monitoring. They analyzed the motivations of patients who
participated in a web-based intensive monitoring study on
the safety of antidiabetic drugs (excluding insulins). In all,
1,332 patients responded to an online questionnaire. The main
motive for participating was altruism, whereas experiencing
ADRs or negative experiences with drugs were generally less
important. The type of patient also played a role: compared to
women, men felt that the potential future benefits were more
important. The overall opinion about the system was positive.
In another study, Härmark et al. (2013b) compared diabetic
patients who participated in web-based intensive monitoring
[i.e., Lareb Intensive Monitoring (LIM)] to a reference diabetes
population. LIM patients were more often men, were generally
younger and healthier (meaning that the sample included a
higher percentage of de novo treated patients), had shorter
diabetes duration, and used less co-medication than the reference
population. The authors concluded that these differences might
lead to underestimations of ADRs. In another study, Härmark
et al. (2013c, 2014) investigated the reasons for patient non-
response to invitations to participate in active monitoring
systems. Among first-time users of antidiabetics, they found that
patients who agreed to participate were on average 4.5 years
younger than non-respondents and used less co-medication.
No gender differences were found. The main reason for
not participating was lack of information at the pharmacy.
However, given the relatively high response rate to the posted
questionnaire, the authors propose that patients are more willing
to participate when they are informed and invited in the
pharmacy.
In conclusion, although patients who participate in web-
based intensive monitoring of drugs show little difference from
reference populations, studies have demonstrated its usefulness
for monitoring ADRs. It is therefore a complementary method to
spontaneous reporting. It is also more proactive, in that it allows
obtaining information on the evolution of ADRs over time and
calculating the incidence for particular ADRs. The drawbacks are
that it includes a limited number of patients and requires more
resources to manage.
In addition to using web-based systems to gather spontaneous
ADR reports and intensive monitoring systems for certain
patients, it has been proposed that comments posted on Internet
forums about the pros and cons of drugs can be analyzed.
Analysis of Online Forum Comments
Schröder et al. (2007) consider online forums a suitable source of
observational information to complement data from randomized
clinical trials. They analysed drug-related problems in outpatient
treatment of Parkinson’s disease that were posted anonymously
on online forums. From the postings, they identified a number
of drug-related problems that were otherwise largely invisible.
These were mainly associated with qualitative treatment aspects
such as medication handling, dosage, and individual ADRs.
They also identified a number of differences between the forum
postings and clinical study data. The online forums focused
more on ADRs that the patients found particularly worrisome.
For example, they reported more ADRs that affected the skin,
including scarring, compared to expectations based on clinical
trials. On the other hand, patients did not recognize ADRs
that affected the metabolic system, for example, without a
physician’s diagnosis, and these were not mentioned on the
forum.
White et al. (2013) also hypothesized that Internet users
might provide early clues about ADRs. Based on the premise
that people would search for information about their conditions
and medications online, they analyzed the Web search log data
(Google, Bing, and Yahoo!) of 80 million consenting users over
18 months. The results showed that search log mining can
contribute to drug safety surveillance. In a subsequent study,
White et al. (2014) confirmed that the performance of ADR
detection via search logs is comparable and complementary to
detection using the adverse event reporting system (AERS) of
the USA’s Food and Drug Administration (FDA). They showed
that when these two types of data are combined, ADR detection
accuracy can be improved by 19% over the use of each data source
independently.
Similarly, Abou Taam et al. (2014) suggest that analyses
of data from Internet sites can provide useful complementary
information. They analyzed data from three French websites
that featured discussion lists or forums on health issues. Their
objective was to explore patients’ perceptions of the risks
associated with benflurorex before, during, and after it was
withdrawn from the market. Before the drug was withdrawn,
most posted comments concerned treatment effectiveness. Once
the risk for valvulopathy was broadcast in the media, most of
the postings contained warnings or ADR reports. Afterwards,
most of the comments expressed anger about the healthcare
system, or anxiety about undesirable cardiovascular effects. Using
a similar approach, Chee et al. (2009) used personal health
messages from online communities to show that trends in
people’s positive and negative feelings about particular drugs can
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be tracked over time. Changes in feelings corresponded to FDA
announcements (e.g., market withdrawal of a drug) and other
forms of publicity. For example, after Tysabri was introduced
[to treat multiple sclerosis (MS)], feelings were initially positive,
then became increasingly negative during a recall period, and
subsequently returned to positive (albeit slightly less positive
than originally) after it was reintroduced. The authors propose
that this type of analysis can ultimately lead to the development
of population health measurement tools to predict treatment
outcomes. Thus, overall negative feelings about a particular
drug or trend changes may indicate dissatisfaction, warranting
further investigation into the causes of dissatisfaction, including
ADRs.
Wu et al. (2013) found that online discussions can be
monitored to detect previously unrecognised ADRs. They
developed new methods for building an integrated knowledge
base for ADR-related information and for monitoring online
discussions about drugs and found that both methods can
identify ADRs for four recently recalled drugs. Moreover, online
discussions made it easier to detect ADRs much earlier than
official announcements.
Pages et al. (2014) showed that data from website forums
are considered relevant and worth sharing, and can be used to
complement more conventional pharmacovigilance methods to
detect AEs related to oral antineoplastic (OAN) drugs. However,
some differences were found between AEs for OAN drugs
reported on online forums and those recorded in the French
pharmacovigilance database (FPVD): more musculoskeletal
disorder reports were posted on patient websites, along with
fewer skin disorders, and AEs reported on patient websites were
less serious.
Several studies have addressed the contribution of discussions
on social networking sites such as Facebook and Twitter.
Freifeld et al. (2014) evaluated the content of Twitter
posts concerning possible AEs. Of 6.9 million Twitter posts,
4,401 possible AEs (Proto-AEs) were identified out of 60,000
examined. Overall, the Proto-AEs reported on Twitter showed
similar distribution profiles to data from the traditional
pharmacovigilance system (the above-mentioned FAERS). The
authors concluded that the patients who reported on Twitter
showed a range of sophistication when describing their
experience, and that the contributory role of this type of
information has yet to be clearly established. After assessing the
potential of a using a Facebook group to identify potential ADRs,
Knezevic et al. (2011) feel that such groups could be used to
stimulate spontaneous ADR reporting.
The above-presented studies demonstrate that comments
posted on online forums can be analyzed to gather information
on potential ADRs. Notably, they can improve the understanding
of patients’ experiences and concerns. In addition, the two
studies by White et al. (2013, 2014) show that search log
analysis produces valuable data. For instance, according to
Noren (2014), many people who would hesitate to share adverse
experiences in public might use Internet search engines to look
for relevant information, and might agree to share this type of
data.
TABLE 1 | Pros and cons of the various methods for gathering pharmacovigilance data.
Pros Cons
Web-based spontaneous reporting of adverse drug reactions (ADRs).
– Faster and easier via the Internet than written reports.
– More accessible for individuals with Internet access.
– Requires fewer resources to manage data collection.
– Targets individuals with ready Internet access, and is consequently unrepresentative of
populations.
– Requires investment on the part of patients (taking the time to report ADRs).
– Accuracy and reliability of reports are difficult to verify.
– Patient identity is difficult to verify. Are they actually patients?
Intensive drug monitoring studies.
– Other aspects can be gathered at the same time: medication use,
dosage taken, compliance, perceived effectiveness.
– Allows gathering longitudinal data.
– Targets individuals with ready Internet access.
– Participating patients are not necessarily representative of the reference population.
– Requires more resources to gather data (patient recruitment, emailing, etc.).
– Studies generally include a limited number of patients, and are consequently not
accessible to large populations.
Analysis of online forum postings.
– Individuals who post comments are not required to follow a particular
procedure or approach.
– The data are already shared on the Internet. Consequently, patients
are not required to do anything further.
– The data are already online, and therefore do not need to be
gathered.
– Allows rapid feedback on new-to-market drugs.
– Not everyone likes to post their comments on online forums. Only individuals who are
willing to their experiences online will participate. Therefore, comments are
unrepresentative of the population.
– Targets individuals with ready Internet access.
– Does not allow follow-up over time.
– Risk of excluding individuals such as the elderly or illiterate.
– Impossible to verify the accuracy or reliability of comments.
– The analysis of forum comments is complex and time-consuming.
Use of mobile phone systems to monitor drug effects.
– Allows reaching a wide population worldwide, including developing
countries.
– Allows reaching individuals immediately at any location.
– Excludes individuals without access to a cell phone, smartphone, or tablet.
– Risks excluding the elderly.
– Requires more resources to gather data (patient recruitment, SMS messaging, etc.).
– Studies generally include a limited number of patients, and are consequently not
accessible to large populations.
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Web-based data analysis may be considered a complementary
information source to spontaneous reports and intensive
monitoring of particular medications.
In addition to these three monitoring methods, all of
which rely on the Internet to gather information, other
pharmacovigilance methods that use other ehealth technologies
have been explored, and mobile phones in particular.
Use of Mobile Ehealth Systems (Cell
Phones, Smartphones, and Tablets) to
Monitor ADRs
In Europe, some enterprises are developing user-friendly apps
that enable everyone to use a smartphone or tablet to make
spontaneous ADR reports. However, these mobile ehealth
systems are more often found in developing countries.
According to Gaur (2011), cellular technology provides an
inexpensive means of monitoring ADRs in the developing
world. The lack of resources in these parts makes it difficult
to carry out large-scale pharmacovigilance programs. At the
same time, cellular phones are in widespread use in such
countries.
For example, Adedeji et al. (2011) showed that telephones can
be used to obtain information on ADRs from individuals who
purchased antimalarials. Participants were actively monitored by
calls to their mobile phones throughout a 28-days monitoring
period. The response rate was 57% in the first 24 h after purchase,
dropping to 33% by day 4. The authors did not find any increase
in known ADRs during the monitoring period. They suggest that
mobile phones provide a practical means to report ADRs related
to antimalarials, and could be the method of choice in Africa,
where cell phones and cell phone coverage are currently driving
innovative agricultural and trade practices.
Similarly, Baron et al. (2013) showed that mobile phone-
based tools, and particularly short message service (SMS) text
messages, can be used to gather information on ADRs following
vaccination. In spring 2012 they recruited 184 participants from
an international vaccination center. Two days after vaccination,
participants received an automatically generated SMS text asking
whether any AEs had occurred. Of those who agreed to
participate, 28.3% did not reply, 54.9% sent an immediate SMS
reply, and 16.8% sent a reply after more prompting. The authors
concluded that an SMS-based system can be useful for gathering
patients’ notifications, particularly in an urban setting. In Saudi
Arabia, Aljadhey et al. (2012) corroborated the feasibility of
gathering information on potential ADRs associated with the
H1N1 vaccine in children via mobile phone contact with child
caregivers.
Curioso et al. (2005) previously showed in a pilot project
that cell phones could be used for real-time collection of
ADRs in urban and rural Peru. Their objective was to develop
an interactive computer-based system using cell phones to
collect data on ADRs related to metronidazole use (to treat
bacterial vaginosis) in prostitutes. However, in their study,
public health workers reported the ADRs, and not prostitutes
themselves. The ADRs were reported as codes via cell phones
and stored in a secure online database. Data were immediately
accessible worldwide, and could be analyzed and transmitted
by email and SMS to team leaders to provide real-time
alerts.
In sum, mobile phones have been demonstrated useful for
gathering information on drug safety, especially in developing
countries. Such ehealth systems show great promise for
developing countries, where access to cell phones is more readily
available compared to Internet-enabled computers. Nevertheless,
studies have shown that responses tend to decrease over time,
which hinders long-term follow-up.
DISCUSSION
It is increasingly recognized that patients can play a major
role in identifying, describing, and preventing drug-related
harm. Patients can contribute in several ways: they can submit
spontaneous reports to pharmacovigilance agencies, participate
in postmarketing monitoring programs and studies, and posts
warnings and comments on online forums. In addition, in order
to get patients involved, ehealth technologies are gaining in use,
including websites, online forums, cell phones, apps, and surely
more to come.
In recent years, patients have had access to more and
more ways to make online reports of ADRs. Moreover, many
studies have demonstrated that patient reports have provided
TABLE 2 | State of the art, avenue for further development and issues that
remain unresolved.
State of the art.
Recent developments in pharmacovigilance.
– Patient participation.
– The ability to make spontaneous ADR reports online.
– Web-based intensive drug monitoring studies.
– Analysis of online forum postings.
– The use of mobile ehealth systems to monitor ADRs.
Avenues for further development.
Future challenges.
– Raise patients’ awareness that they can report ADRs themselves.
– Raise awareness among patients and healthcare professionals of the
importance of reporting ADRs so as to increase the number of reports.
– Standardise report questionnaires across countries to facilitate comparison
and coding of data stored in databases.
– Rally all sections of the population to participate: the elderly, lower
socioeconomic status groups, and the less educated.
– Explore strategies to generate online message sharing via health-specific social
sites such as PatientsLikeMe, MedHelp, Inspire, CureTogether, etc.
– Make better use of databases generated by various methods (data mining
issues).
Issues that remain unresolved.
Risks and liabilities
– Under-reporting of ADRs.
– Inherent differences between patient and healthcare professional reports.
– The population selection bias involved in many data collection methods.
– Overlooking the fact that the different ways to gather information on ADRs are
complementary.
– The complexity of analyzing data gathered from online discussions and search
engines.
– Data security and confidentiality issues for databases.
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useful information that complements reports by HCPs, and
that can help identify potential new ADRs. Therefore, patient
participation should improve pharmacovigilance. The data
they provide is useful for combining with the data gathered
in postmarketing monitoring studies, including intensive
monitoring with patient follow-up over time as well as more
specific studies. In addition, studies are making greater use of
ehealth technologies. For instance, questionnaires can be emailed
to patients, or patients can be contacted on their cell phones.
Finally, patients’ online forum postings about the risks and
benefits of medications can round out the picture. Each of these
methods has its pros and cons (see the Table 1 below), but taken
together, they provide as complete a representation of ADRs as
possible at this time.
Despite the promise of these innovative pharmacovigilance
methods, a few issues remain unaddressed (see Table 2).
Generally, studies that analyzed spontaneous ADR reports
considered all reports made by patients and HCPs, including
paper, phone, and online reports. Therefore, it is unknown
whether the differences observed between patient and HCP
reports would vary (or not) according to the reporting mode.
It is also unknown whether the ability to make online reports
has increased the number of ADR reports, and whether patients
as well as HCPs tend to use online reports more than paper
or phone reports. With respect to cell phone apps that allow
spontaneous reports anywhere, anytime, no study to date has
specifically assessed the usefulness and added benefits of this
technology.
Although online reports have certain advantages, notably
more rapid data processing, they also have some drawbacks.
It is more difficult to verify whether the ADR reporter is
actually a patient, that the patient is taking the medication
properly, and that the ADR has been reported just one time.
Some people, intentionally or not, may report ADRs by mistake,
or they may be mistaken in their perception of the ADR.
Furthermore, patient-reported ADRs are usually not validated
by a physician’s opinion. Moreover, some ADRs are undetected
in medical exams, and may be undetected by the patient as
well. In these cases, patient-reported information would be
questionable. Yet decision makers need reliable information.
Despite all these caveats, however, patient-generated data can
be useful, especially for developing hypotheses about potential
side-effects.
There is also the possibility of bias related to certain
characteristics of patients who participate in pharmacovigilance,
especially when ehealth tools are involved. For instance, data
are gathered less often from older patients and those with
lower socioeconomic status and less education. And, because
pharmacovigilance centers are tending to use electronic reports,
there is a risk of excluding individuals without Internet access
or who are inept at using it. Some web-based postmarketing
monitoring studies have demonstrated that participating patients
are younger and have fewer pathologies. Similarly, the profiles of
those who post comments on online forums should be taken into
consideration. For example, we might suppose that fewer older
individuals would participate in such forums. Adams (2013)
examined comments posted on a Dutch website about patients’
experiences with medications. One potential drawback to the
use of this type of information for pharmacovigilance is user
representativeness. For instance, users who contribute to the site
need to have a certain level of computer expertise, knowledge
about health, and the ability to describe their experiences so that it
is useful for others. The author also notes that more medications
are consumed by certain demographic groups such as the
elderly, people of low socioeconomic status, and patients with
certain chronic conditions. As evidenced by the characteristics
of site users, these are generally not the people who share
their experiences online. Therefore, the comments cannot be
considered entirely representative of the very groups for whom
pharmacovigilance is the most important. Similarly, the Institute
for Healthcare Informatics (IMS) (Gauntlett et al., 2013) found
that recently developed apps are not well suited for patients with
multiple chronic conditions, who are usually over 65 years old.
Yet these are exactly the patients who are liable to be the biggest
healthcare consumers. What is more, this group contains the
smallest percentage of cell phone users, at only 18% of all users
in the US compared to 54% of 45- to 54-year-olds.
For studies that address cell phone monitoring in developing
countries, it would be equally important to analyze the profiles
of people who use a cell phone and who are able and willing to
respond to surveys. This could help determine whether or not
the probability of participating in such studies is associated with
age, socioeconomic status, and education level.
CONCLUSION
This article confirms the value of involving patients themselves
in pharmacovigilance as well as the usefulness of ehealth tools.
Ehealth solutions facilitate data gathering from patients and
HCPs alike. As such, they make a significant contribution to the
detection of AEs and ADRs. In addition, worldwide collection of
AEs using smart phones might become the leading technique in
Low and Middle Income Countries where broad mobile phone
service can be managed cheaper than Internet communication.
In future, initiatives are needed to better inform the public
that they can make their own reports about ADRs, and the
importance of doing so should be underscored. Strategies for
engaging all sections of the population, including those who are
less tech-adept, should be explored. Finally, the full potential
of the databases generated by diverse ADR gathering methods
should be leveraged.
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